Tafamidis Reduces Death and Hospitalization for Acute Heart Failure in Octogenarian Patients With Transthyretin Cardiac Amyloidosis: A Propensity Score-Weighted Cohort Study.

ABSTRACT:

Background

Transthyretin cardiac amyloidosis results from the deposition of misfolded amyloid fibrils in cardiac tissue, leading to progressive heart failure. Tafamidis, a transthyretin stabilizer, reduces all-cause death and cardiovascular rehospitalization, but its impact on people aged ≥80 years remains underexplored. This study evaluated the effectiveness of tafamidis in octogenarian patients with transthyretin cardiac amyloidosis compared with nonexposed patients.

Methods

A propensity score-weighted cohort study included all patients aged ≥80 years with confirmed transthyretin cardiac amyloidosis (hereditary or wild-type) followed at the French Referral Center for cardiac amyloidosis between 2010 and 2021. Patients who initiated tafamidis after November 1, 2018, and wer

SUBMITTER: Zmuda L 

PROVIDER: S-EPMC12826890 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature